Does J&J's Innovative Medicine Unit Hold the Key to Q2 Sales Growth?

Johnson & Johnson's Innovative Medicine segment is expected to drive Q2 sales growth, buoyed by strong performance from key drugs like Darzalex, Tremfya, and Erleada, alongside contributions from new therapies such as Carvykti. This growth is anticipated despite significant headwinds including the loss of exclusivity for Stelara, which negatively impacted Q1 revenue by 470 basis points and is expected to have a steeper effect in Q2, as well as the impact of Medicare Part D redesign and increased generic competition. J&J projects continued growth for the segment through the year with an estimated 3% CAGR over the next three years, while JNJ shares have outperformed the industry year-to-date, trading at a reasonable valuation of 14.45x forward earnings.

Analysis

Johnson & Johnson's upcoming second-quarter results are centered on the performance of its Innovative Medicine segment, which faces a mix of significant growth drivers and headwinds. The segment's expansion is propelled by strong market share gains and sales from key drugs such as Darzalex, Tremfya, and Erleada, supplemented by a portfolio of new products including Carvykti. However, this growth is being challenged by the loss of exclusivity (LOE) for its multi-billion-dollar drug, Stelara, which already eroded revenue growth by 470 basis points in the first quarter and is expected to have a steeper impact in Q2. Additional pressures include generic competition for drugs like Zytiga and Remicade, declining sales of Imbruvica due to new oral competitors, and the negative financial impact of the Medicare Part D redesign on drugs like Uptravi. Despite these obstacles, the company anticipates continued growth in the segment for the remainder of the year. From a market perspective, JNJ shares have notably outperformed, rising 9.6% year-to-date against a 0.6% industry decline, while trading at a reasonable 14.45x forward earnings multiple, below both its industry peer group and its five-year average.

Key Decisions for Investors

• Investors should scrutinize the upcoming July 16 earnings report to assess whether growth from key products like Darzalex and Carvykti can effectively offset the anticipated steeper revenue decline from Stelara's loss of exclusivity.
• Given the stock's 9.6% year-to-date outperformance and a valuation below historical and industry averages, the current price may represent a reasonable entry point, contingent on management providing strong guidance that confirms its ability to navigate patent cliffs.
• The primary risks to monitor are the quantifiable financial impacts of biosimilar competition on Stelara and the effects of the Medicare Part D redesign, as these factors will be critical to achieving the projected 3% CAGR for the Innovative Medicine unit.